Manuscripts and Publications

Filters: Keyword is Middle Aged  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Martinez CH, Diaz AA, Meldrum C, Curtis JL, Cooper CB, Pirozzi C, Kanner RE, Paine R, Woodruff PG, Bleecker ER et al..  2017.  Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.. Am J Respir Crit Care Med. 195(4):464-472.
Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL et al..  2016.  Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts.. Chest. 149(4):927-35.
Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, R Barr G, Bleecker ER et al..  2019.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.. J Clin Invest. 129(1):169-181.
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, C Davis W, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG et al..  2017.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.. N Engl J Med. 377(10):911-922.
Radicioni G, Ceppe A, Ford AA, Alexis NE, R Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN et al..  2021.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 9(11):1241-1254.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Belz DC, Woo H, Putcha N, Paulin LM, Koehler K, Fawzy A, Alexis NE, R Barr G, Comellas AP, Cooper CB et al..  2022.  Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR.. Sci Total Environ. 829:154694.
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galbán CJ, Ross BD, Hoffman EA et al..  2018.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.. Am J Respir Crit Care Med. 198(2):265-267.
Paulin LM, Gassett AJ, Alexis NE, Kirwa K, Kanner RE, Peters S, Krishnan JA, Paine R, Dransfield M, Woodruff PG et al..  2020.  Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers.. JAMA Intern Med. 180(1):106-115.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, Wise RA, Kanner RE, Bowler RP, R Barr G et al..  2018.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.. Respir Res. 19(1):20.
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.. JCI Insight. 5(3)
Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, R Barr G, Krishnan JA, Cooper C, Labaki WW et al..  2020.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.. Chest. 157(4):856-865.
B
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
C
Bhatt SP, Nath HP, Kim Y-I, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC et al..  2018.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.. Respir Res. 19(1):257.
Chin AT, Rylance J, Makumbirofa S, Meffert S, Vu T, Clayton J, Mason P, Woodruff P, Metcalfe J.  2019.  Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study.. Int J Tuberc Lung Dis. 23(2):203-211.
Moll M, Sakornsakolpat P, Shrine N, Hobbs BD, DeMeo DL, John C, Guyatt AL, McGeachie MJ, Gharib SA, Obeidat M'en et al..  2020.  Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.. Lancet Respir Med. 8(7):696-708.
Nishida K, Brune KA, Putcha N, Mandke P, O'Neal WK, Shade D, Srivastava V, Wang M, Lam H, An SS et al..  2017.  Cigarette smoke disrupts monolayer integrity by altering epithelial cell-cell adhesion and cortical tension.. Am J Physiol Lung Cell Mol Physiol. 313(3):L581-L591.
Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, O'Neal WK, Comellas AP, Han MK, Dransfield MT et al..  2020.  Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene.. Chest. 158(6):2333-2345.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Woodruff PG, R Barr G, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE et al..  2016.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.. N Engl J Med. 374(19):1811-21.
Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP et al..  2020.  Comparison of Proteomic Assessment Methods in Multiple Cohort Studies.. Proteomics. 20(12):e1900278.

Pages